Aanastra Inc and Divincell present preclinical data on its p53 tumor suppressor rescue and its in vivo anti-CD19

par Aude | Mai 13, 2025 | Non classé

Aanastra Inc and Divincell present preclinical data on its p53 tumor suppressor rescue and its in vivo anti-CD19 CART programs at the 28th Annual Meeting of the American Society for Gene and Cell Therapy (ASGC). May 13-17, 2025, in New Orleans....

Aanastra Inc and DivIncell present preclinical data on its in vivo anti-CD19 CART program at the AACR Annual

par Aude | Avr 25, 2025 | Non classé

Aanastra Inc and DivIncell present preclinical data on its in vivo anti-CD19 CART program at the AACR Annual Meeting, Chicago, April 25-30, 2025 

Aanastra Inc and Divincell SAS present a “Peptide-based nanoparticle platform for extrahepatic

par Aude | Jan 28, 2025 | Non classé

Aanastra Inc and Divincell SAS present a “Peptide-based nanoparticle platform for extrahepatic targeted delivery of mRNA and gene editing” at the 4th mRNA Based Therapeutics Summit Europe, Frankfurt. January 28-30, 2025 

Aanastra Inc and Divincell SAS present a “A new Peptide nanoparticle platform for extrahepatic targeted delivery of therapeutic mRNAs”

par Aude | Oct 22, 2024 | Non classé

Aanastra Inc and Divincell SAS present a “A new Peptide nanoparticle platform for extrahepatic targeted delivery of therapeutic mRNAs” and “mRNA delivery for Factor VIII rescue in hemophilia and gene editing of PCSK9 for cholesterol lowering” at the 31st European...

Aanastra Inc and Divincell to Showcase its Peptide-RNA Therapeutics Technology

par Aude | Mai 7, 2024 | Non classé

Aanastra Inc and Divincell to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024, Baltimore. May 07-11, 2024